CVS Health Corp (CVS) Position Lifted by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC increased its stake in shares of CVS Health Corp (NYSE:CVS) by 72.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,344 shares of the pharmacy operator’s stock after purchasing an additional 43,139 shares during the period. CVS Health accounts for about 2.6% of Prime Capital Investment Advisors LLC’s holdings, making the stock its 6th biggest position. Prime Capital Investment Advisors LLC’s holdings in CVS Health were worth $8,057,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the stock. Canton Hathaway LLC acquired a new position in CVS Health in the 3rd quarter valued at $126,000. MCF Advisors LLC raised its holdings in CVS Health by 284.1% in the 3rd quarter. MCF Advisors LLC now owns 1,713 shares of the pharmacy operator’s stock valued at $135,000 after acquiring an additional 1,267 shares during the last quarter. Mainstay Capital Management LLC ADV acquired a new position in CVS Health in the 2nd quarter valued at $154,000. Sageworth Trust Co raised its holdings in CVS Health by 260.2% in the 3rd quarter. Sageworth Trust Co now owns 2,215 shares of the pharmacy operator’s stock valued at $174,000 after acquiring an additional 1,600 shares during the last quarter. Finally, LFA Lugano Financial Advisors SA acquired a new position in CVS Health in the 2nd quarter valued at $176,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Shares of NYSE CVS opened at $74.09 on Friday. CVS Health Corp has a 52-week low of $60.14 and a 52-week high of $83.88. The firm has a market cap of $78.01 billion, a PE ratio of 11.23, a P/E/G ratio of 1.10 and a beta of 0.98. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.44 and a quick ratio of 1.94.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Tuesday, November 6th. The pharmacy operator reported $1.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.71 by $0.02. CVS Health had a net margin of 1.65% and a return on equity of 18.69%. The company had revenue of $47.27 billion during the quarter, compared to analysts’ expectations of $47.22 billion. During the same period in the previous year, the company earned $1.50 EPS. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. As a group, sell-side analysts expect that CVS Health Corp will post 7.03 EPS for the current fiscal year.

In related news, CFO David M. Denton sold 25,159 shares of the company’s stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $80.13, for a total transaction of $2,015,990.67. Following the completion of the sale, the chief financial officer now directly owns 403 shares of the company’s stock, valued at approximately $32,292.39. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Eva C. Boratto sold 13,311 shares of the company’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the sale, the executive vice president now directly owns 55,162 shares of the company’s stock, valued at $4,256,299.92. The disclosure for this sale can be found here. Insiders have sold a total of 74,233 shares of company stock valued at $5,932,565 over the last three months. Corporate insiders own 0.53% of the company’s stock.

Several brokerages have weighed in on CVS. Goldman Sachs Group reiterated a “neutral” rating and issued a $87.00 price target on shares of CVS Health in a report on Thursday, November 29th. ValuEngine upgraded CVS Health from a “sell” rating to a “hold” rating in a report on Thursday, October 11th. Argus boosted their price target on CVS Health to $100.00 and gave the company a “buy” rating in a report on Tuesday, November 13th. Loop Capital set a $80.00 price target on CVS Health and gave the company a “hold” rating in a report on Wednesday, November 28th. Finally, Evercore ISI began coverage on CVS Health in a report on Wednesday, November 28th. They issued an “outperform” rating and a $89.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $90.69.

TRADEMARK VIOLATION NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/cvs-health-corp-cvs-position-lifted-by-prime-capital-investment-advisors-llc.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Recommended Story: Cost of Capital Explained

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply